Agenus Inc. (NASDAQ:AGEN) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Monday, July 24th.
AGEN has been the subject of several other research reports. Maxim Group reaffirmed a “buy” rating and set a $7.00 target price on shares of Agenus in a research note on Sunday, April 23rd. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Wednesday, July 5th. ValuEngine raised shares of Agenus from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. Finally, HC Wainwright set a $5.00 price objective on shares of Agenus and gave the company a “hold” rating in a research note on Saturday, May 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $5.88.
Shares of Agenus (NASDAQ:AGEN) traded up 1.71% during midday trading on Monday, reaching $3.57. 483,682 shares of the company were exchanged. The firm has a 50-day moving average of $4.25 and a 200 day moving average of $3.90. Agenus has a 52 week low of $3.20 and a 52 week high of $7.49. The firm’s market capitalization is $355.97 million.
Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. The company had revenue of $4.21 million during the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. Agenus’s revenue was down 36.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.33) earnings per share. On average, equities research analysts expect that Agenus will post ($1.13) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/19/agenus-inc-nasdaqagen-stock-rating-upgraded-by-bidaskclub-updated-updated-updated.html.
Hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its stake in Agenus by 6.7% in the second quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock worth $248,000 after buying an additional 4,006 shares during the last quarter. Voya Investment Management LLC boosted its stake in Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,381 shares during the last quarter. OxFORD Asset Management LLP bought a new stake in Agenus during the second quarter worth $141,000. Vanguard Group Inc. boosted its stake in Agenus by 5.2% in the second quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock worth $13,805,000 after buying an additional 174,162 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Agenus by 4.1% in the second quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock worth $3,682,000 after buying an additional 37,239 shares during the last quarter. 41.54% of the stock is currently owned by institutional investors.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
What are top analysts saying about Agenus Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agenus Inc. and related companies.